{"id":"high-dose-influenza-vaccination","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site soreness"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Fatigue"},{"rate":"15-20","effect":"Headache"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Standard influenza vaccines contain 15 micrograms of hemagglutinin per strain, while high-dose formulations contain 60 micrograms per strain. This increased antigen quantity triggers more robust activation of B cells and T cells, resulting in higher antibody titers and improved protection, particularly in older adults with waning immune function. The enhanced immunogenicity translates to better clinical efficacy in preventing influenza infection and reducing severe outcomes.","oneSentence":"High-dose influenza vaccination stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:44.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza in adults aged 65 years and older"},{"name":"Prevention of influenza in immunocompromised populations"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT06451159","phase":"PHASE1","title":"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bruce Cree","startDate":"2024-06-20","conditions":"Progressive Multiple Sclerosis","enrollment":10},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06907511","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-04-17","conditions":"Pandemic Influenza Immunization, Healthy Volunteers","enrollment":720},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT05517174","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2022-09-22","conditions":"Influenza","enrollment":332438},{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT06506812","phase":"PHASE4","title":"Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2025-05-31","conditions":"Influenza","enrollment":466320},{"nctId":"NCT04487041","phase":"PHASE4","title":"Tfh Dysfunction in HIV and Aging","status":"RECRUITING","sponsor":"University of Miami","startDate":"2020-10-30","conditions":"Human Influenza","enrollment":400},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT05875961","phase":"PHASE1","title":"Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-15","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":600},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT06088563","phase":"NA","title":"Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-10-26","conditions":"Vaccination; Infection","enrollment":38},{"nctId":"NCT06567366","phase":"PHASE2","title":"CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09","conditions":"Large B-cell Lymphoma","enrollment":45},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05970744","phase":"PHASE1","title":"Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Respiratory Syncytial Virus Infections","enrollment":60},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT04176133","phase":"PHASE2","title":"Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination","status":"COMPLETED","sponsor":"Robert J. Pignolo","startDate":"2019-10-30","conditions":"Healthy","enrollment":61},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT03599739","phase":"","title":"Adjuvanted Influenza Vaccination Year 2 Follow-On Survey","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2018-07-13","conditions":"Influenza, Influenza-like Illness, Influenza, Human","enrollment":598},{"nctId":"NCT02982915","phase":"PHASE1, PHASE2","title":"Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty","status":"COMPLETED","sponsor":"Longeveron Inc.","startDate":"2016-11","conditions":"Aging Frailty","enrollment":62},{"nctId":"NCT05048589","phase":"PHASE2","title":"Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2021-10-01","conditions":"Influenza","enrollment":12551},{"nctId":"NCT03681860","phase":"PHASE1, PHASE2","title":"EMaBS TB Vaccine Study","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-01","conditions":"Safety, Immunogenicity","enrollment":72},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT02908269","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-09-15","conditions":"Influenza","enrollment":180},{"nctId":"NCT02268500","phase":"PHASE4","title":"VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2014-09","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT03996538","phase":"PHASE1","title":"Vaccination Efficacy With Metformin in Older Adults","status":"COMPLETED","sponsor":"UConn Health","startDate":"2019-06-05","conditions":"Aging, Age-Related Immunodeficiency, Vaccine Response Impaired","enrollment":26},{"nctId":"NCT02554188","phase":"PHASE2","title":"Fasting-mimicking Diet and Immunosenescence","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2019-05-01","conditions":"Immunosenescence","enrollment":""},{"nctId":"NCT01945268","phase":"PHASE4","title":"Influenza Vaccine To Prevent Adverse Vascular Events:Pilot","status":"COMPLETED","sponsor":"McMaster University","startDate":"2015-04","conditions":"Heart Failure","enrollment":107},{"nctId":"NCT01924169","phase":"PHASE2","title":"Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-24","conditions":"Hematologic Disorder","enrollment":3},{"nctId":"NCT01815268","phase":"PHASE4","title":"High-Dose Influenza Vaccine in Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2013-02","conditions":"Influenza","enrollment":823},{"nctId":"NCT01720277","phase":"PHASE4","title":"High Dose Influenza Vaccine in Nursing Home - Pilot Study","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2012-09","conditions":"Influenza","enrollment":2957},{"nctId":"NCT01262846","phase":"PHASE4","title":"Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-11","conditions":"HIV Infection","enrollment":195},{"nctId":"NCT02311855","phase":"PHASE4","title":"Duration of Immune Response to Influenza Vaccination in Patients With RA","status":"COMPLETED","sponsor":"Bassett Healthcare","startDate":"2014-08","conditions":"Rheumatoid Arthritis","enrollment":87},{"nctId":"NCT00680069","phase":"PHASE1, PHASE2","title":"H5N1 (Clade 2) Vaccination of Adults and Elderly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Influenza","enrollment":517},{"nctId":"NCT01740310","phase":"NA","title":"Vaccine Acceptance in Pregnant Minority Women","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-07","conditions":"Pregnancy","enrollment":121},{"nctId":"NCT01189123","phase":"NA","title":"Cell Mediated Immunity in Older Adults","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-08","conditions":"Immunity to Influenza Vaccine","enrollment":105},{"nctId":"NCT01675284","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine","status":"COMPLETED","sponsor":"Medigen Biotechnology Corporation","startDate":"2012-08","conditions":"Bird Flu, Avian Influenza, Influenza A(H5N1)","enrollment":36},{"nctId":"NCT00439335","phase":"PHASE1, PHASE2","title":"Higher Dose Intradermal H5 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-03","conditions":"Influenza","enrollment":227},{"nctId":"NCT01304563","phase":"NA","title":"2010/2011 Trivalent Influenza Vaccination","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-11","conditions":"Influenza","enrollment":240},{"nctId":"NCT01022905","phase":"PHASE4","title":"Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2009-11","conditions":"HIV Infection, Rheumatic Disease, Cancer","enrollment":1141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluzone high dose quadrivalent"],"phase":"marketed","status":"active","brandName":"High dose influenza vaccination","genericName":"High dose influenza vaccination","companyName":"University of Miami","companyId":"university-of-miami","modality":"Biologic","firstApprovalDate":"","aiSummary":"High-dose influenza vaccination stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}